BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33508120)

  • 1. CSN5 Promotes Carcinogenesis of Thyroid Carcinoma Cells Through ANGPTL2.
    Xie P; Wang H; Fang J; Du D; Tian Z; Zhen J; Liu Y; Ding Y; Fu B; Liu F; Huang D; Yu J
    Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33508120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis.
    Wan Z; Huang S; Mo F; Yao Y; Liu G; Han Z; Chen M; Zhiyun L
    Exp Cell Res; 2019 Nov; 384(2):111646. PubMed ID: 31560888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.
    Li J; Li Y; Wang B; Ma Y; Chen P
    Biochem Biophys Res Commun; 2018 Jun; 500(2):132-138. PubMed ID: 29596838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.
    Liu H; Hu J; Pan H; Luo D; Huang M; Xu W
    Dig Dis Sci; 2018 Jan; 63(1):155-165. PubMed ID: 29189991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
    Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
    J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSN5 promotes the invasion and metastasis of pancreatic cancer by stabilization of FOXM1.
    Mao L; Le S; Jin X; Liu G; Chen J; Hu J
    Exp Cell Res; 2019 Jan; 374(2):274-281. PubMed ID: 30352219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein.
    Huang M; Xiong H; Luo D; Xu B; Liu H
    Exp Cell Res; 2020 Mar; 388(2):111876. PubMed ID: 31991125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression.
    Adler AS; Littlepage LE; Lin M; Kawahara TL; Wong DJ; Werb Z; Chang HY
    Cancer Res; 2008 Jan; 68(2):506-15. PubMed ID: 18199546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
    Ma Y; Xia P; Wang Z; Xu J; Zhang L; Jiang Y
    Neoplasia; 2021 Sep; 23(9):912-928. PubMed ID: 34325342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles for CSN5 in control of p53/MDM2 activities.
    Zhang XC; Chen J; Su CH; Yang HY; Lee MH
    J Cell Biochem; 2008 Mar; 103(4):1219-30. PubMed ID: 17879958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation.
    Zhang S; Hong Z; Chai Y; Liu Z; Du Y; Li Q; Liu Q
    Biochem Biophys Res Commun; 2017 Jun; 488(1):101-108. PubMed ID: 28479251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
    Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
    Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The putative oncotarget CSN5 controls a transcription-uncorrelated p53-mediated autophagy implicated in cancer cell survival under curcumin treatment.
    Zhang QY; Jin R; Zhang X; Sheng JP; Yu F; Tan RX; Pan Y; Huang JJ; Kong LD
    Oncotarget; 2016 Oct; 7(43):69688-69702. PubMed ID: 27626169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging roles of Jab1/CSN5 in cancer.
    Wang L; Zheng JN; Pei DS
    Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
    Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer.
    Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W
    Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The COP9 signalosome stabilized MALT1 promotes Non-Small Cell Lung Cancer progression through activation of NF-κB pathway.
    Wang Y; Deng X; Xie J; Lu T; Qian R; Guo Z; Zeng X; Liao J; Ding Z; Zhou M; Niu X
    Cell Biol Toxicol; 2024 Jun; 40(1):45. PubMed ID: 38864940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex.
    Tomoda K; Kubota Y; Arata Y; Mori S; Maeda M; Tanaka T; Yoshida M; Yoneda-Kato N; Kato JY
    J Biol Chem; 2002 Jan; 277(3):2302-10. PubMed ID: 11704659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5.
    Wang S; Pan Y; Zhang R; Xu T; Wu W; Zhang R; Wang C; Huang H; Calin CA; Yang H; Claret FX
    Oncogene; 2016 Nov; 35(47):6096-6108. PubMed ID: 27157611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells.
    Bhansali M; Shemshedini L
    Mol Endocrinol; 2014 Jun; 28(6):834-45. PubMed ID: 24725084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.